{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:15:27Z","timestamp":1783574127485,"version":"3.55.0"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To report a case of retinal capillary hemangioblastoma (RCH) regression in a patient with von Hippel\u2013Lindau (VHL) disease following treatment with systemic belzutifan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 49-year-old female with VHL disease presented with a retinal capillary hemangioblastoma in the left eye that had been previously treated with laser therapy. She subsequently developed a new retinal lesion and interval growth of a renal intraparenchymal mass, for which systemic belzutifan was initiated. Four months after treatment initiation, a reduction in the size of the retinal lesions was observed, along with decreased perfusion and vascularity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Systemic belzutifan therapy for VHL disease may induce regression of retinal capillary hemangioblastomas and can be effective as either a primary or an adjunctive treatment modality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1870341","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:21:18Z","timestamp":1783570878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Regression of retinal capillary hemangioblastoma with systemic belzutifan in von Hippel\u2013Lindau disease: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Angelica Aja Dangca","family":"Alcoreza","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Quirino Memorial Medical Center","place":["Quezon City, Philippines"]},{"name":"Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryn","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyeop","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1186\/s12885-025-15192-8","article-title":"Belzutifan for patients with von Hippel\u2013Lindau disease\u2013associated heterogeneous tumors: a retrospective single-center analysis","volume":"25","author":"Rhein","year":"2025","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2024.102011","article-title":"Belzutifan-induced regression of retinal capillary hemangioblastoma: a case series","volume":"33","author":"Ercanbrack","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000001452","article-title":"Successful treatment of von Hippel\u2013Lindau disease\u2013associated retinal capillary hemangioblastoma with belzutifan in a pediatric patient","volume":"18","author":"Jones","year":"2024","journal-title":"Retinal cases Brief Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.009","article-title":"Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel\u2013Lindau disease","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ophtha.2022.07.007","article-title":"Systemic treatment reduces von Hippel\u2013Lindau\u2013associated retinal capillary hemangioblastoma","volume":"130","author":"Fairbanks","year":"2023","journal-title":"Ophthalmology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003973","article-title":"Successful treatment response of a juxtapapillary retinal capillary hemangioblastoma due to von Hippel\u2013Lindau syndrome with belzutifan in a pediatric patient","volume":"44","author":"Mustafi","year":"2024","journal-title":"Retina"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2024.05.025","article-title":"Belzutifan as the first-line treatment for a challenging von Hippel\u2013Lindau\u2013related retinal hemangioblastoma: successful treatment of a case and review of the literature","volume":"59","author":"Aykut","year":"2024","journal-title":"Can J Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26805","article-title":"The role of hypoxia-inducible factor-2 alpha in angiogenesis","volume":"233","author":"Befani","year":"2018","journal-title":"J Cell Physiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1870341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:21:18Z","timestamp":1783570878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1870341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":9,"alternative-id":["10.3389\/fonc.2026.1870341"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1870341","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1870341"}}